This application requests support for personnel, operating expenses and travel related to the conduct of cooperative clinical trials at the University of Kentucky under the auspices of the Southwest Oncology Group (SWOG). This support will solidify and enhance and already substantial contribution by this institution to the SWOG program in both leadership (with Dr. John Macdonald, M.D., as Chairman of the Gastrointestinal Study Group) and patient accessions (70 over the last 9 months of 1986). Within the Lucille Parker Markey Cancer Center (LPMCC) the University has developed a sound framework through which to facilitate such studies, including a Clinical Protocol Office established as one of its central """"""""Core"""""""" facilities supported in part through a Cancer Center Support Grant from the National Cancer Institute. In addition, the LPMCC has developed an interactive computerized patient information management system which is specifically designed to facilitate the conduct, management and analysis of protocol studies. The funds requested in this proposal will supplement the fundamental operations of the Protocol Office and will support and consolidate the efforts of the various oncologic specialities specifically toward their participation in SWOG protocols. Significant travel support is requested to permit key participating personnel to attend appropriate officially designated meetings of the SWOG Cooperative Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046136-05
Application #
3558740
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-01-01
Project End
1992-12-31
Budget Start
1992-01-01
Budget End
1992-12-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Type
Schools of Medicine
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Nand, Sucha; Othus, Megan; Godwin, John E et al. (2013) A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood 122:3432-9
Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25
Mahadevan, Daruka; Unger, Joseph M; Spier, Catherine M et al. (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371-9
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Petersdorf, Stephen H; Kopecky, Kenneth J; Slovak, Marilyn et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854-60
Gadgeel, Shirish M; Lew, Danika L; Synold, Timothy W et al. (2013) Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol 72:1089-96
von Mehren, Margaret; Rankin, Cathryn; Goldblum, John R et al. (2012) Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118:770-6
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9

Showing the most recent 10 out of 93 publications